Ibrutinib Therapy for Chronic Lymphocytic Leukemia Complicated with Secondary Serous Adenocarcinoma of the Peritoneum

Özet

1. Strati P, Parikh SA, Chaffee KG, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol 178: 394-402, 2017. 2. Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood 133: 2031-2042, 2019. 3. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 373: 2425-2437, 2015. 4. Pula B, Budziszewska BK, Rybka J, et al. Comparable efficacy of Idelalisib plus Rituximab and Ibrutinib in relapsed/ refractory chronic lymphocytic leukemia: A retrospective case matched study of the Polish Adult Leukemia Group (PALG). Anticancer Res 38: 3025-3030, 2018. 5. Jamroziak K, Pula B, Walewski J. Current treatment of chronic lymphocytic leukemia. Curr Treat Options Oncol 18: 5, 2017. 6. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1: 80-87, 2015. 7. Iskierka-Jazdzewska E, Pula B, Szeremet A, et al. Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG). Adv Clin Exp Med 28: 1051-1057, 2019. 8. Ryan CE, Sahaf B, Logan AC, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood 128: 2899-2908, 2016. 9. Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E. Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors. Cancer Treat Rev 58: 41-50, 2017. 10. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer 17: 57, 2018.